Should I Buy IMA? IMA 2026 Analysis

Should You Buy ImageneBio Inc (IMA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

6.070

1 Day change

2.53%

52 Week Range

18.000

Analysis Updated At

2026/03/06

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

ImageneBio Inc (IMA) is not a strong buy for a beginner investor with a long-term horizon and $50,000-$100,000 to invest. The stock lacks positive momentum, clear trading signals, or significant catalysts to justify immediate investment. Given the bearish technical indicators, lack of recent news, and weak financial performance, holding off on investing in IMA is the prudent choice at this time.

Technical Analysis

The MACD is negative and expanding downward, RSI is neutral at 25.727, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key pivot levels, with resistance at 7.062 and support at 6.137, indicating a bearish trend.

Positive Catalysts

NULL identified. No recent news or significant trading trends from hedge funds or insiders.

Neutral/Negative Catalysts

Bearish technical indicators, lack of positive news or trading signals, and weak financial performance.

Financial Performance

In Q3 2025, ImageneBio reported no revenue growth (0% YoY), a net income loss of -$25.63M (up 150.39% YoY), and an EPS of -3.01 (up 18.50% YoY). While there is improvement in net income and EPS, the company remains unprofitable.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target data available.

3 Analyst Rating

Wall Street analysts forecast IMA stock price to rise

2 Buy

0 Hold

1 Sell

Moderate Buy

Current: 5.920

Low

Averages

High

Current: 5.920

Low

Averages

High

Wedbush

Martin Fan

Neutral -> Underperform

downgrade

$23 -> $2

AI Analysis

2025-11-25

Reason

Wedbush

Martin Fan

Price Target

$23 -> $2

AI Analysis

2025-11-25

downgrade

Neutral -> Underperform

Reason

Wedbush analyst Martin Fan downgraded ImageneBio to Underperform from Neutral with a price target of $2, down from $23, while assuming coverage of the stock. The firm recommends investors avoid ImageneBio shares unless the company either gains a development partner, or shifts its focus to a new indication, citing high development costs, the company's reliance on a single asset and indication, a limited catalyst calendar, and what it views as competitors with equivalent or superior product profiles.

Leerink

Outperform

initiated

$30

2025-10-24

Reason

Leerink

Price Target

$30

2025-10-24

initiated

Outperform

Reason

Leerink initiated coverage of ImageneBio (IMA) with an Outperform rating and $30 price target. The firm views shares as "dramatically undervalued," particularly following a selloff in the wake of disappointing competitor Sanofy's (SNY) amlitelimab results on September 4. Leerink believes ImageneBio's lead asset IMG-007, a non-depleting anti-OX40 monoclonal antibody, is a potential blockbuster for atopic dermatitis. Early clinical data for IMG-007 suggests compelling efficacy at Week 16 compared to Dupixent. Competing drug candidate Phase 3 disappointments from Amgen's (AMGN) OX40 rocatinlimab and Sanofi's OX40L amlitelimab have dampened investor sentiment toward the OX40-OX40L class. This yields a favorable setup for IMG-007 to deliver a superior "trifecta" competitive profile, the firm argues.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for IMA

Unlock Now

IMA Should I Buy

IMA Should I Buy

Should You Buy ImageneBio Inc (IMA) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch